LFX 453

Drug Profile

LFX 453

Alternative Names: LFX-453

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Actinic keratosis; Genital warts

Most Recent Events

  • 01 May 2016 Novartis completes a phase-II trial in Genital warts in USA (NCT02482428)
  • 01 May 2015 Phase-II clinical trials in Genital warts in USA (Topical) (NCT02482428)
  • 01 Mar 2015 Phase-II clinical trials in Actinic keratosis in Austria (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top